Autosomal Recessive Polycystic Kidney Disease
文献摘要
Autosomal recessive polycystic kidney disease (ARPKD) is a rare genetic disorder primarily affecting the kidneys and liver. Clinicians should recognize early signs such as enlarged, echogenic kidneys in utero or during infancy. ARPKD most commonly results from mutations in Polycystic Kidney and Hepatic Disease 1 (PKHD1), leading to renal cysts and congenital hepatic fibrosis in early life. About half of the patients with ARPKD develop end-stage renal failure requiring renal replacement therapy, including dialysis or kidney transplantation, within the first 2 decades of life. The 2 varieties of polycystic kidney disease based on inheritance include the relatively common autosomal dominant and the much rarer autosomal recessive types. These 2 forms have distinct clinical and genetic features. See "Renal Cystic Disease" for further information. Autosomal dominant polycystic kidney disease (ADPKD), previously called adult polycystic kidney disease, is a multisystem progressive cystic disorder primarily affecting the kidneys. The disorder is characterized by bilateral renal cysts that progressively lead to fibrosis, architectural distortion, hypertension, and progressive renal failure, with symptoms typically beginning around 30 years of age. See "Renal Cystic Disease" for further information. In adults, ADPKD is the most frequent genetic cause of renal failure and end-stage kidney disease. See "Autosomal Dominant Polycystic Kidney Disease" for further information. ARPKD primarily involves the kidney and liver. Historically referred to as infantile polycystic kidney disease, it can present in neonatal, infantile, juvenile, or even adult populations. Hence, the old nomenclature of adult and infantile polycystic kidney disease is no longer used. ARPKD is characterized by renal distal tubule and collecting duct cyst formation, hepatic biliary duct ectasia/malformation, and fibrosis involving both the liver and kidneys. This disorder is a ciliopathy that presents with cysts along the distal renal tubules and collecting ducts, whereas in ADPKD, cysts can develop anywhere along the nephron. Cysts in ARPKD are mostly microcystic in early childhood, may develop calcifications, and can produce renal calculi. In older children, the cysts become larger and concentrated in the renal medulla. The clinical presentation of ARPKD varies significantly, with some patients diagnosed at a young age having more severe symptoms than those diagnosed when older. ARPKD is always associated with liver bile duct malformations, both intrahepatic and extrahepatic. Liver manifestations vary from mild cholestasis to hepatic fibrosis, portal vein hypertension, esophageal varices, cholangitis, and cirrhosis. A key factor in understanding the presentations of ARPKD is that previously 30% to 40% of affected neonates were reported to die perinatally, typically due to respiratory distress from pulmonary hypoplasia from oligohydramnios related to decreased fetal urine production. A 2004 study of 164 perinatal survivors reported survival rates of 85% and 82% at 1 and 10 years, respectively. Kidney survival rates, defined as need for renal replacement treatment or death from end-stage renal disease (ESRD), at 5, 10, and 20 years were 86%, 71%, and 42%, respectively. Some of the perinatal data may have been derived from older studies conducted before technical advances in neonatal intensive care, which have reduced perinatal mortality to about 20% within the first month of life.